首页> 外文期刊>Journal of gastroenterology >Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
【24h】

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

机译:RAMUCILUMAB作为肝细胞癌晚期患者的二线治疗:日本亚群分析达重试验

获取原文
获取原文并翻译 | 示例
           

摘要

Bckground REACH evaluated ramucirumab in the second-line treatment of patients with advanced hepatocellular carcinoma. In the intent-to-treat population (n = 565), a significant improvement in overall survival (OS) was not observed. In patients with an elevated baseline alpha-fetoprotein (AFP) level (400 ng/mL or greater), an improvement in OS was demonstrated. An analysis of the Japanese patients in REACH was performed.
机译:BCKGround REACH评估了RAMUCIRUMAB在先进的肝细胞癌患者的二线治疗中。 在意图群体(n = 565)中,未观察到整体存活(OS)的显着改善。 在升高的基线α-胎蛋白(AFP)水平(400ng / ml或更大)患者中,证明了OS的改善。 进行了对日本院患者的分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号